Long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers: Results from a multicenter study LUD2015-005. This is an ASCO Meeting Abstract from the 2023 ...
Endoscopic prediction of depth of tumor invasion in early gastric cancer in the upper third of the stomach. A phase 2 study of durvalumab plus DOS (docetaxel, oxaliplatin, S-1) neoadjuvant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results